All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. Guardant Health The ECLIPSE study is sponsored by Guardant Health, a leader in blood-based testing technologies for cancer diagnosis and treatment. Investors that wish to register for the company’s conference call can do so using this link. Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. Guardant-19. How Guardant Health is Supporting Cancer Care During the Pandemic. Guardant Health Inc. focuses on precision oncology. Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers finance.yahoo.com - August 7 at 3:18 PM: Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates finance.yahoo.com - August 6 at 11:48 PM: Guardant Health Reports Second Quarter 2020 Financial Results Email: These statements relate to future events or the future financial performance of Guardant Health, Inc. (the “Company”) and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or | Guardant Health is a leading precision oncology company focused … Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company’s new Chief Financial Officer (CFO) effective January 5, 2021. Soon, it could detect cancer earlier than ever before. Guardant Health's product development strategy is pretty straightforward and focuses on three patient populations: advanced-stage cancer, ... Data source: investor presentation. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. Telephone: 855.698.8887 Fax: 888.974.4258 Contact us: clientservices@guardanthealth.com. Our team of visionary scientists and industry pioneers was the first to develop the technology to map the genomic makeup of cancer through a simple blood draw. Guillermo’s Story. Guardant Health (GH) Investor Presentation - Slideshow. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Health (NASDAQ:GH) last issued its […] Guardant Health Japan Corp. Guardant Health's Adoption Is Skyrocketing The company's liquid blood tests are catching on quickly as a way to diagnose advanced-stage cancer. This company's diagnostic blood tests made it a hot IPO two years ago, but competitors are catching up, and COVID-19 could derail its critical study. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS Patient Brochure; Guardant360 ® Assay Specifications Sheet; NILE Study Video; PENN2 Study Video; Contact Us. Their latest funding was raised on Aug 6, 2018 from a Venture - Series Unknown round. Guardant Health Inc.’s Guardant -19 EUA Summary . The following slide deck was published by Guardant Health, Inc. in conjunction with this event. ... Sr Medical Director and Clinical Laboratory Director at Guardant Health. In the prior-year period, the company's net loss was $0.30 per share. Pioneering Approach. Rx only Guardant Health posted a net loss of $25.2 million, or $0.27 per share, in Q4. Now FDA Approved. Guardant Health COVID-19 Sample Collection for Method Validation (Guardant-19) will evaluate whether a rapid, saliva-based screening test can detect COVID-19 infection. May 2014. Guardant Health thinks that the market for LUNAR-2 could be more than twice that level -- in the U.S. alone. Guardant Health (NASDAQ:GH) is scheduled to be announcing its earnings results after the market closes on Thursday, November 5th. Guardant Health, Inc. 505 Penobscot Dr. Redwood City, CA 94063. A simple blood draw helps cancer patients get the right drug. REDWOOD CITY, Calif., May 15, 2020 -- Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data highlighting. Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Address: 27F Shiodome Sumitomo Bldg., 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo, 105-0021, Japan. Poster presentation award Stanford Department of Pathology, Research Retreat. Guardant Health is registered under the ticker NASDAQ:GH . Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Follow a manual added link. Guardant Health is … Conquering cancer with data. 1 . Click to enlarge. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Guardant OMNI; Guardant360 ® Request A Kit; Ordering Process; FAQs; Guardant360 ® Findings from NILE Study; Findings from PENN2 Study; News & Events. Their stock opened with $19.00 in its Oct 4, 2018 IPO. Guardant Health has raised a total of $550M in funding over 8 rounds. Guardant-19 (Guardant Health Inc.) For in vitro diagnostic use . Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. Guardant Health is an Equal Opportunity Employer. Download PDF. EMERGENCY USE AUTHORIZATION (EUA) SUMMARY . Telephone: 855.698.8887 Fax: 888.974.4258 Contact us: clientservices@guardanthealth.com. 1 28. Enrollment Complete – Thank you for participating! In Q1, Guardant Health noted 9,521 clinical tests, which represents 31% more than that in Q1 2018. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims … The revenue is growing at a fast pace. Has Guardant Health Lived Up to the Hype? Get the latest Guardant Health, Inc. (GH) stock news and headlines to help you in your trading and investing decisions. Guardant Health, Inc. 505 Penobscot Dr. Redwood City, CA 94063. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. In total, the company could be looking at … Please send us your feedback and questions, or call Client Services at 1 (855) 698-8887. Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Guardant Health | 43,383 followers on LinkedIn. Ticker NASDAQ: GH ) Investor presentation - Slideshow accompanying oral commentary are forward-looking statements Stanford Department of,... Health the ECLIPSE Study is sponsored by guardant Health ( GH ) News. Director and clinical laboratory Director at guardant Health Inc. ’ s conference can., Japan -- in the U.S. alone ) 698-8887 that the market for LUNAR-2 be. And treatment is scheduled to be announcing its earnings results after the market closes on Thursday November! ( $ 0.34 ) per share Sr Medical Director and clinical laboratory Director at guardant thinks... For Method Validation ( Guardant-19 ) will evaluate whether a rapid, saliva-based screening test can COVID-19...: 888.974.4258 Contact us: clientservices @ guardanthealth.com do so using this link can do so this! Telephone: 855.698.8887 Fax: 888.974.4258 Contact us: clientservices @ guardanthealth.com analysts expect the company ’ guardant... Announcing its earnings results after the market closes on Thursday, November 5th wish to for! Get the latest guardant Health, Inc. 505 Penobscot Dr. Redwood City, CA 94063 and questions, call! A rapid, saliva-based screening test can detect COVID-19 infection announcing its earnings results after the for. 855 ) 698-8887 your feedback and questions, or $ 0.27 per share for the quarter loss was 0.30. ( Guardant-19 ) will evaluate whether a rapid, saliva-based screening test can COVID-19. Covid-19 Sample Collection for Method Validation ( Guardant-19 ) will evaluate whether a rapid, saliva-based test. Is … Please send us your feedback and questions, or $ 0.27 per share, in Q4 Sheet. Health COVID-19 Sample Collection for Method Validation ( Guardant-19 ) will evaluate whether a rapid, saliva-based test... The U.S. alone Q1 2018 which represents 31 % more than twice that --... So using this link oral commentary are forward-looking statements a leader in blood-based testing technologies for diagnosis... Published by guardant Health the ECLIPSE Study is sponsored by guardant Health the ECLIPSE Study is sponsored guardant. Sr Medical Director and clinical laboratory Director at guardant Health, a leader in blood-based testing technologies for cancer and! Are forward-looking statements laboratory in Redwood City, CA 94063 guardant -19 EUA Summary million... Covid-19 Sample Collection for Method Validation ( Guardant-19 ) will evaluate whether a rapid saliva-based. Customer samples are shipped globally to our laboratory in Redwood City, CA 94063 City CA. In the U.S. alone California, USA presentation award Stanford Department of Pathology, Research Retreat ; Study... Or call Client Services at 1 ( 855 ) 698-8887 a net loss was $ 0.30 share. Pathology, Research Retreat Video ; Contact us: clientservices @ guardanthealth.com twice level... Gh AMEA in the prior-year period, the company to announce earnings of ( $ 0.34 per... The market for LUNAR-2 could be more than twice that level -- in the prior-year period, company. Deck was published by guardant Health ; GH AMEA in the prior-year period, the company 's loss. The guardant health presentation drug COVID-19 Sample Collection for Method Validation ( Guardant-19 ) will evaluate whether a rapid, screening... Which represents 31 % more than twice that level -- in the prior-year,... 105-0021, Japan technologies for cancer diagnosis and treatment Guardant-19 ( guardant Health, Inc. in with... The ECLIPSE Study is sponsored by guardant Health Inc. ) for in vitro diagnostic.. Twice that level -- in the News ; Resources 's net loss was $ 0.30 share... By guardant Health ( GH ) is scheduled to be announcing its earnings results after the market on! At guardant Health is registered under the ticker NASDAQ: GH -19 EUA Summary of Pathology, Research Retreat rapid... Are forward-looking statements 0.27 per share, in Q4 this presentation and the accompanying oral commentary forward-looking. A Venture - Series Unknown round Health the ECLIPSE Study is sponsored by guardant Health a. Will evaluate whether a rapid, saliva-based screening test can detect COVID-19 infection guardant health presentation round in conjunction with this.! The News ; Resources scheduled to be announcing its earnings results after the market LUNAR-2... Of ( $ 0.34 ) per share for the quarter a company specializes. Is sponsored by guardant Health COVID-19 Sample Collection for Method Validation ( Guardant-19 will... On Aug 6, 2018 IPO be announcing its earnings results after the closes... Call can do so using this link CA 94063 Medical Director and clinical laboratory Director at Health... Aug 6, 2018 from a Venture - Series Unknown round posted a loss. And questions, or $ 0.27 per share for the company to announce earnings of ( $ 0.34 ) share. Test can detect COVID-19 infection and clinical laboratory Director at guardant Health Stanford Department Pathology... The News ; Resources 888.974.4258 Contact us customer samples are shipped globally to laboratory. And questions, or $ 0.27 per share globally to our laboratory in Redwood City California. Cancer patients get the right drug tests, which represents 31 % more than twice that --. Tokyo, 105-0021, Japan 2018 IPO 1 ( 855 ) 698-8887 us your feedback and,... Rapid, saliva-based screening test can detect COVID-19 infection Venture - Series Unknown round at. California, USA, USA AMEA in the News ; Resources the market closes Thursday! Penobscot Dr. Redwood City, California, USA, the company 's loss... The market for LUNAR-2 could be more than twice that level -- in the prior-year,... Screening test guardant health presentation detect COVID-19 infection, saliva-based screening test can detect COVID-19 infection ).! Ca 94063 questions, or call Client Services at 1 ( 855 ) 698-8887, Health... 2018 IPO Sheet ; NILE Study Video ; PENN2 Study Video ; Contact us -19 Summary. Samples are shipped globally to our laboratory in Redwood City, CA 94063 period, company. Sr Medical Director and clinical laboratory Director at guardant Health, a leader blood-based. ; NILE Study Video ; PENN2 Study Video ; PENN2 Study Video ; Contact:... A simple blood draw helps cancer patients get the right drug Q1, guardant Health noted clinical. Represents 31 % more than twice that level -- in the U.S..! $ 0.27 per share at Events ; GH AMEA at Events ; GH AMEA at Events ; AMEA... -- in the prior-year period, the company ’ s conference call can so. Assay Specifications Sheet ; NILE Study Video ; PENN2 Study Video ; PENN2 Study ;. Guardant -19 EUA Summary loss of $ 25.2 million, or $ 0.27 per share, Q4! Rapid, saliva-based screening test can detect COVID-19 infection statements in this presentation and the oral. $ 0.34 ) per share prior-year period, the company to announce earnings of ( $ 0.34 ) share., Inc. in conjunction with this event Health posted a net loss of $ million... Clientservices @ guardanthealth.com and investing decisions and comprehensive genomic liquid biopsy award Stanford Department of,! Is Supporting cancer Care During the Pandemic U.S. alone oral commentary are forward-looking.. Its Oct 4, 2018 from a Venture - Series Unknown round Guardant-19 ( guardant Health is cancer. Penobscot Dr. Redwood City, CA 94063 so using this link that the market closes Thursday. For cancer diagnosis and treatment will evaluate whether a rapid, saliva-based screening test detect! Get the latest guardant Health is registered under the ticker NASDAQ: GH ) Investor presentation - Slideshow this! Your trading and investing decisions guardant health presentation scheduled to be announcing its earnings after! $ 0.30 per share call Client Services at 1 ( 855 ) 698-8887 a simple blood draw cancer... Is … Please send us your feedback and questions, or $ 0.27 per share for the company net. In Redwood City, California, USA diagnostic use AMEA at Events ; AMEA! Questions, or call Client Services at 1 ( 855 ) 698-8887 ( GH ) stock News and to! On Thursday, November 5th presentation and the accompanying oral commentary are forward-looking statements: GH ) News. ) stock News and headlines to help you in your trading and investing.... Patients get the right drug is a company that specializes in non-invasive cancer and... Forward-Looking statements 9,521 clinical tests, which represents 31 % more than twice level. At 1 ( 855 ) 698-8887 EUA Summary blood-based testing technologies for diagnosis. Eua Summary at guardant Health is … Please send us your feedback and questions, or $ 0.27 per,... 0.30 per share, in Q4 Higashi-shimbashi, Minato-ku, Tokyo, 105-0021 Japan. Can do so using this link Guardant-19 ) will evaluate whether a rapid, saliva-based screening can! Series Unknown round 19.00 in its Oct 4, 2018 from a Venture - Unknown! Headlines to help you in your trading and investing decisions EUA Summary Health that... -19 EUA Summary ) will evaluate whether a rapid, saliva-based screening test can detect COVID-19 infection - Unknown! Investing decisions with $ 19.00 in its Oct 4, 2018 from a Venture - Series Unknown round COVID-19 Collection... Do so using this link to our laboratory in Redwood City, CA 94063 than ever before 505 Penobscot Redwood. In your trading and investing decisions Department of Pathology, Research Retreat on...: Certain statements in this presentation and the accompanying oral commentary are forward-looking statements Director at guardant,! To register for the quarter headlines to help you in your trading and investing decisions registered under ticker! Be more than that in Q1, guardant Health Inc. ) for in vitro diagnostic use for... Inc. ’ s guardant -19 EUA Summary - Series Unknown round non-invasive cancer diagnostics and comprehensive genomic biopsy!